[go: up one dir, main page]

AR023824A1 - Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado. - Google Patents

Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado.

Info

Publication number
AR023824A1
AR023824A1 ARP000102097A ARP000102097A AR023824A1 AR 023824 A1 AR023824 A1 AR 023824A1 AR P000102097 A ARP000102097 A AR P000102097A AR P000102097 A ARP000102097 A AR P000102097A AR 023824 A1 AR023824 A1 AR 023824A1
Authority
AR
Argentina
Prior art keywords
ccr5
antagonist
pegilado
hiv
interferon alfa
Prior art date
Application number
ARP000102097A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR023824A1 publication Critical patent/AR023824A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe el uso de un interferon-alfa pegilado, y el antagonista CCR5, adicionalmente en asociacion con por lo menos uno de ribavirina, IL-2, IL-12,pentafusida sola o en combinacion con una terapia de droga anti HIV-1, por ejemplo HAART, para la preparacion de un medicamento para el tratamiento deinfecciones de HIV-1 así como también coinfecciones de HIV-1 y HCV en pacientes adultos y pediátricos que no han sido sometidos a tratamiento, asícomo también pacientes adultos y pediátricos que hanexperimentado tratamiento.
ARP000102097A 1999-05-04 2000-05-02 Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado. AR023824A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30489799A 1999-05-04 1999-05-04

Publications (1)

Publication Number Publication Date
AR023824A1 true AR023824A1 (es) 2002-09-04

Family

ID=23178462

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102097A AR023824A1 (es) 1999-05-04 2000-05-02 Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado.

Country Status (21)

Country Link
EP (1) EP1175224B1 (es)
JP (1) JP2002543144A (es)
CN (1) CN1349408A (es)
AR (1) AR023824A1 (es)
AT (1) ATE289516T1 (es)
AU (1) AU776541B2 (es)
BR (1) BR0010593A (es)
CA (1) CA2365900A1 (es)
DE (1) DE60018273T2 (es)
ES (1) ES2238277T3 (es)
HK (1) HK1039278B (es)
HU (1) HUP0202734A3 (es)
MX (1) MXPA01011116A (es)
MY (1) MY127670A (es)
NO (1) NO328679B1 (es)
NZ (1) NZ514519A (es)
PE (1) PE20010283A1 (es)
PT (1) PT1175224E (es)
TW (1) TWI289454B (es)
WO (1) WO2000066141A2 (es)
ZA (1) ZA200108870B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
WO2004080966A1 (ja) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
WO2004092169A1 (ja) 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
EP1616862A4 (en) * 2003-04-18 2008-07-16 Ono Pharmaceutical Co HETEROCYCLIC NITROGEN COMPOUND AND USE THEREOF
EP1591539B1 (en) 2004-04-29 2007-10-03 F. Hoffmann-La Roche Ag NS5A nucleoside sequence variation as a marker
PE20090123A1 (es) 2004-09-13 2009-03-10 Ono Pharmaceutical Co Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo
BRPI0609251A2 (pt) * 2005-02-23 2010-03-09 Schering Corp derivados de piperidinil piperazina úteis como inibidores de receptores de quimiocinas
WO2006129679A1 (ja) 2005-05-31 2006-12-07 Ono Pharmaceutical Co., Ltd. スピロピペリジン化合物およびその医薬用途
ES2427989T3 (es) 2005-10-28 2013-11-05 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
ES2407115T3 (es) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
CA2644368A1 (en) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
EP2042503B1 (en) 2006-05-16 2013-01-30 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
EP2055705A4 (en) 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
AU2012338581B2 (en) 2011-11-18 2016-12-08 Nxera Pharma Uk Limited Muscarinic M1 receptor agonists
KR102503400B1 (ko) 2014-01-08 2023-02-23 이뮤노베이티브 테라피스, 엘티디. 인간 면역 결핍 바이러스/후천성 면역 결핍증의 치료
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
WO1997016204A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Continuous low-dose cytokine infusion therapy
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos

Also Published As

Publication number Publication date
ES2238277T3 (es) 2005-09-01
WO2000066141A3 (en) 2001-02-08
WO2000066141A2 (en) 2000-11-09
ATE289516T1 (de) 2005-03-15
CN1349408A (zh) 2002-05-15
EP1175224A2 (en) 2002-01-30
MXPA01011116A (es) 2002-06-04
MY127670A (en) 2006-12-29
AU776541B2 (en) 2004-09-16
TWI289454B (en) 2007-11-11
HUP0202734A3 (en) 2003-11-28
HK1039278B (en) 2005-06-30
DE60018273T2 (de) 2005-08-18
NO20015367D0 (no) 2001-11-02
HK1039278A1 (en) 2002-04-19
HUP0202734A2 (hu) 2002-12-28
CA2365900A1 (en) 2000-11-09
NZ514519A (en) 2003-07-25
PT1175224E (pt) 2005-07-29
BR0010593A (pt) 2002-02-13
DE60018273D1 (de) 2005-03-31
AU4681500A (en) 2000-11-17
PE20010283A1 (es) 2001-03-16
NO328679B1 (no) 2010-04-26
JP2002543144A (ja) 2002-12-17
NO20015367L (no) 2002-01-03
ZA200108870B (en) 2003-03-26
EP1175224B1 (en) 2005-02-23

Similar Documents

Publication Publication Date Title
AR023824A1 (es) Terapia de hiv combinacion de antagonista ccr5-interferon alfa pegilado.
AR023541A1 (es) Terapia de combinacion para vhc
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
PE119199A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion por hepatitis c cronica
AR019551A1 (es) Uso de la ribavirina en combinacion con el interferon alfa para la fabricacion de un medicamento para la terapia de combinacion para erradicar hcv-rna detectable en pacientes no afectados a tratamiento antiviral que tienen infeccion de hepatitis c cronica
BR0114636A (pt) Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
EP2356990A3 (en) Liposome treatment of viral infections
PT1242119E (pt) Combinacoes para o tratamento de infeccoes por virus adn incluindo um diuretico de ansa e um glicosido cardiotonico
BR0108997A (pt) Terapia imune adjuvante para hiv
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
CO5160259A1 (es) Interferon alfa pegilado en la terapia contra el hiv
BR9915644A (pt) Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus
AR039915A1 (es) Tratamiento de la hepatitis c en la poblacion asiatica
ECSP003462A (es) Terapia de hiv de combinacion de antagonista ccr5 - interferon alfa pegilado (caso ino1024k)
BRPI0409711A (pt) tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina
EP1240899A3 (en) Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
BR0008269A (pt) Uso de uma preparação de m. vaccae, e, método para tratamento de infecção viral crÈnica, excluindo infecção por hiv
James Ribavirin approved for hepatitis C combination treatment
IL154299A0 (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
Scheibel Five-drug or six-drug antiretroviral therapy--conversation with Steven Scheibel, MD Interview by John S. James
Fernández et al. Interferon alfa for chronic hepatitis C infection
ECSP003446A (es) Terapia de combinacion para vhc
Gilden IL-2 taken to HAART
Lumb First International Workshop on HIV and Hepatitis Co-infection

Legal Events

Date Code Title Description
FB Suspension of granting procedure